Want to see STRO full AI Analyst Report?
Total Valuation
Sutro Biopharma has a market cap or net worth of $348.87M. The enterprise value is $635.68.
Market Cap$348.87M
Enterprise Value$635.68
Share Statistics
Sutro Biopharma has 16,581,171 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding16,581,171
Owned by Insiders0.81%
Owned by Institutions57.12%
Financial Efficiency
Sutro Biopharma’s return on equity (ROE) is 1.44 and return on invested capital (ROIC) is -98.52%.
Return on Equity (ROE)1.44
Return on Assets (ROA)-1.10
Return on Invested Capital (ROIC)-98.52%
Return on Capital Employed (ROCE)-1.06
Revenue Per Employee800.66K
Profits Per Employee-1.49M
Employee Count128
Asset Turnover0.59
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Sutro Biopharma is ―. Sutro Biopharma’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.96
PB Ratio-0.74
Price to Fair Value-0.74
Price to FCF-0.55
Price to Operating Cash Flow-2.40
PEG Ratio0.02
Income Statement
In the last 12 months, Sutro Biopharma had revenue of 102.48M and earned -191.09M in profits. Earnings per share was -22.49.
Revenue102.48M
Gross Profit95.16M
Operating Income-104.95M
Pretax Income-191.18M
Net Income-191.09M
EBITDA-145.65M
Earnings Per Share (EPS)-22.49
Cash Flow
In the last 12 months, operating cash flow was -145.17M and capital expenditures -446.00K, giving a free cash flow of -145.62M billion.
Operating Cash Flow-145.17M
Free Cash Flow-145.62M
Free Cash Flow per Share-8.78
Dividends & Yields
Sutro Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.31
52-Week Price Change151.52%
50-Day Moving Average26.29
200-Day Moving Average21.66
Relative Strength Index (RSI)37.31
Average Volume (3m)987.85K
Important Dates
Sutro Biopharma upcoming earnings date is Nov 11, 2026, TBA (Confirmed).
Last Earnings DateAug 12, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Sutro Biopharma as a current ratio of 2.01, with Debt / Equity ratio of -10.44%
Current Ratio2.01
Quick Ratio2.01
Debt to Market Cap0.00
Net Debt to EBITDA0.29
Interest Coverage Ratio-2.75
Taxes
In the past 12 months, Sutro Biopharma has paid -93.00K in taxes.
Income Tax-93.00K
Effective Tax Rate<0.01
Enterprise Valuation
Sutro Biopharma EV to EBITDA ratio is -0.38, with an EV/FCF ratio of -0.31.
EV to Sales0.55
EV to EBITDA-0.38
EV to Free Cash Flow-0.31
EV to Operating Cash Flow-0.32
Balance Sheet
Sutro Biopharma has $164.35M in cash and marketable securities with $10.78M in debt, giving a net cash position of $153.56M billion.
Cash & Marketable Securities$164.35M
Total Debt$10.78M
Net Cash$153.56M
Net Cash Per Share$9.26
Tangible Book Value Per Share-$15.59
Margins
Gross margin is 97.20%, with operating margin of -102.41%, and net profit margin of -186.45%.
Gross Margin97.20%
Operating Margin-102.41%
Pretax Margin-186.55%
Net Profit Margin-186.45%
EBITDA Margin-142.12%
EBIT Margin-149.26%
Analyst Forecast
The average price target for Sutro Biopharma is $51.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$51.17
Price Target Upside123.63% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast-56.25%
EPS Growth Forecast30.97%